Spots Global Cancer Trial Database for anetumab ravtansine
Every month we try and update this database with for anetumab ravtansine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | NCT03126630 | Pleural Maligna... | Anetumab Ravtan... Laboratory Biom... Pembrolizumab Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | Neoplasms | BAY94-9343 | 20 Years - | Bayer | |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | NCT03023722 | Pancreatic Canc... | anetumab ravtan... | 18 Years - | Yale University | |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | NCT03126630 | Pleural Maligna... | Anetumab Ravtan... Laboratory Biom... Pembrolizumab Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma | NCT02839681 | Lung Neoplasms | Anetumab Ravtan... Blood test | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | NCT03023722 | Pancreatic Canc... | anetumab ravtan... | 18 Years - | Yale University | |
| Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer | NCT03023722 | Pancreatic Canc... | anetumab ravtan... | 18 Years - | Yale University | |
| Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | NCT03455556 | Mesothelin Posi... Stage III Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... | Anetumab Ravtan... Atezolizumab Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03587311 | Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... | Anetumab Ravtan... Bevacizumab Paclitaxel | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
